CEO Pernilla Sandwall presents the company at Swiss Nordic Bio 30 March

The conference will take place in Zurich on March 30, 2023. Pernilla will present the company and the drug candidate Foxy-5, which aims to prevent the incidence of metastases. Pernilla will also talk about the interesting observations made in connection with the ongoing phase 2 study and the implications for the continuation of the study. The study is conducted on patients affected by colon cancer.

Swiss Nordic Bio is a high-level partnering and investor conference that gathers life science professionals from Switzerland and the Nordic countries under one roof and is aimed at connecting healthcare innovations, investor and industry. The conference is organised by Vator Securities and Business Sweden together with Nordic and Swiss partners.

For further information:

Pernilla Sandwall, CEO, WntResearch AB
e-mail: pernilla.sandwall@wntresearch.com

About Wntresearch AB

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the metastatic process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com. Follow WntResearch on Linked in